Variable expression of CYP and Pgp genes in the human small intestine

European Journal of Clinical Investigation

Volumn 33, Issue 6, 2003, Pages 493-499

  Lindell, Monica ^a,b   Karlsson, M O ^a   Lennernas H ^a   Pahlman L ^a   Lang, M A ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Cytochrome P450; Human; Intestine; mRNA expression; Pgp; Variability

Indexed keywords

ACETYLSALICYLIC ACID; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; GLYCOPROTEIN P; OMEPRAZOLE;

ADULT; AGED; ARTICLE; CORRELATION ANALYSIS; DUODENUM BIOPSY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL INTESTINE; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; CYTOCHROME P-450 ENZYME SYSTEM; DUODENUM; FEMALE; HUMANS; INTESTINE, SMALL; MALE; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0038236976     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2003.01154.x     Document Type: Article

References (31)

1. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-8.
2. Zhang Q-Y, Dunbar D, Ostrowska A, Zeisloft S, Yang J, Kaminsky LS. Characterization of human small intestinal cytochrome P-450. Drug Metab Disp 1999;27:804-9.
3. Koskela S, Hakkola J, Hukkanen J, Pelkonen O, Sorri M, Saranen A et al. Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem Pharmacol 1999;57:1407-1413.
4. Obach RS, Zhang Q-Y, Dunbar D, Kaminsky LS. Metabolic characterization of the major human small intestinal cytochrome P450s. Drug Metab Disp 2001;29:347-52.
5. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ et al. The P450 superfamily, update on new sequences, gene mapping, accession number and nomenclature. Pharmacogenetics 1996;6:1-42.
6. Lown KS, Ghosh M, Watkins PB. Sequences of intestinal and hepatic cytochrome P450 3A4 cDNAs are identical. Drug Metab Disp 1998;26 185-7.
7. Tukey RH, Strassburg CP. Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharrn 2001;59:405-14.
8. Vogel A, Kneip S, Barut A, Ehmer U, Tukey RH, Manns MP et al. Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. Gastroenterology 2001;121:1136-44.
9. Wacher VJ, Silverman JA, Zhang Y, Benet LZ. Role of P-glycoprotein and cytochrome P450, 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998;87:1322-30.
10. Katoh M, Nakajima M, Yamazaki H, Yokoi T. Inhibitory effects of CYP3A4 substrates and their metabolites on p-glycoprotein-mediated transport. Eur J Pharm Sci 2001;21:505-13.
11. Zhang Y, Benet LZ. The gut as a barrier to drug absorption. Combined role of cytochrome P450, 3A and P-Glycoprotein. Olin Pharmacokinet 2001;40:159-68.
12. Chambers JM, Hastie TJ, eds. Statistical Models. London: S. Chapman & Hall; 1993.
13. Benet LZ, Wu C-Y, Hebert MF, Wacher VJ. Intestinal drug metabolism and antitransport processes: a potential paradigm shift in oral drug delivery. J Control Release 1996;39:139-43.
14. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-Glycoprotein and Cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996;49:311-8.
15. Wrighton SA, VandenBranden M, Ring BJ. The human drug metabolizing cytochrome P450. J Pharmacokinetics Biopharmaceutics 1996;24:461-73.
16. Doherty MM, Charman WN. The mucosa of the small intestine, how clinically relevant as an organ of drug metabolism? Clin Pharmacokinet 2002;41:235-53.
17. de Waziers I, Cugnenc PH, Yang CS, Leroux J-P, Beaune PH. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 1990;253:387-94.
18. Windmill KF, McKinnon RA, Zhu X, Gaedigk A, Grant DM, McManus ME. The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional localization studies. Mutat Res 1997;376:153-60.
19. Porter TD, Coon MJ. Cytochrome P450. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms. J Biol Chem 1991;266:13469-72.
20. Ramana KV, Kohli KK. Gene regulation Cytochrome P450 - Overview. Indian J Exp Biol 1998;36:437-46.
21. Pelkonen O, Rautio A, Raunio H, Pasanen M. CYP2A6: a human coumarin 7-Hydroxylase. Toxicol 2000;144:139-47.
22. Wong JYY, Seah ES, Lee EJD. Pharmacogenetics. The molecular genetics of CYP2D6 dependent drug metabolism. Ann Acad Med Singapore 2000;29:401-6.
23. Glaeser H, Drescher S, van der Kuip H, Behrens C, Geick A, Burk O et al. Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters. Clin Pharmacol Ther 2002;71:131-40.
24. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3a protein expression. J Clin Invest 1997;99:2545-53.
25. Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V et al. Human Cyp2B6: expression, inducibility catalytic activities. Pharmacogenetics 1999;9:295-306.
26. Gerbal-Chaloin S, Daujat M, Pascussi J-M, Pichard-Garcia L, Vilarem M-J, Maurel P. Transcriptional regulation of CYP2C9 gene. J Biol Chem 2002;277:209-17.
27. Sun D, Lennernäs H, Welage LS, Barnett JL, Landowski CP, Foster D et al. Comparison of human duodenum and Caco-2 gene expression profiles for 12 000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res 2002;19:1398-414.
28. Damme B, Darmer D, Pankow D. Induction of hepatic cytochrome P4502E1 in rats by acetylsalicylic acid or sodium salicylate. Toxicology 1996;106:99-103.
29. Hunt CM, Guzelian PS, Molowa DT, Wright SA. Regulation rat hepatic cytochrome P450 IIE1 primary monolayer hepatocyte culture. 1991;21:1621-31.
30. Kojo A, Viitala P, Pasanen M, Pelkonen O, Raunio H, Juvonen R. Induction of CYP2A5 by pyrazole and its derivatives in mouse primary hepatocytes. Arch Toxicol 1998;72:336-41.
31. Raffalli-Mathieu F, Glisovic T, Ben-David Y, Lang MA. Heterogeneous nuclear ribonucleoprotein A1 and regulation of the xenobiotic-inducible gene Cyp2a5. Mol Pharmacol 2002;61:795-9.